Amarin Corp Plc (AMRN)

[ggwpq]

Interesting insight from the FIELD trial: HDL level doesn't matter (confirm with multiple independent genetic studies), i.e., event rate for high TG/low HDL is more or less the same as high TG alone. See Table 1 of the following link,


http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2646035/#r13

I particularly like the following conclusion,

"Marked hypertriglyceridemia (≥2.3 mmol/l) with or without a low HDL cholesterol level was associated with a higher CVD risk than meeting the criteria for metabolic syndrome, supporting a continuous positive relationship between triglyceride levels and CVD (13). This level of hypertriglyceridemia was associated with increased CVD events in earlier studies (8,14), presumably reflecting a tendency for high nonfasting triglyceride levels and higher numbers of remnant particles and may be associated with more extreme abnormalities in other biological processes (such as oxidative stress, inflammation, and hypercoagulability), leading to more aggressive atherosclerosis (12,14,15)."

I think Amarin derives the 5.9% R-IT placebo group event rate from Table 1.